Importantly, abciximab directly targets vitronectin, whereas fostamatinib has drawn attention for its reported safety and efficacy in phase 3 clinical trials for the treatment of patients with rheumatoid arthritis.29 Here, VTN is linked to rheumatoid arthritis.